Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Optic nerve disorder06.02.08.001; 17.04.05.0040.000112%
Soft tissue disorder15.03.02.012--
Spondylitis15.01.09.0020.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.004746%
Gastrointestinal ulcer07.04.04.0020.000112%Not Available
Lip and/or oral cavity cancer16.13.07.001; 07.21.07.0010.000112%Not Available
Sensation of foreign body08.01.09.0020.000112%Not Available
Urinary tract obstruction20.08.01.0040.000112%
Ulcer haemorrhage08.03.06.003; 24.07.01.0400.000112%Not Available
Autonomic neuropathy17.05.01.009--Not Available
Bone marrow disorder01.05.01.0060.000112%Not Available
Chondropathy15.07.03.0030.000112%Not Available
Disease progression08.01.03.0380.002988%
Disease recurrence08.01.03.0500.000616%Not Available
Obstructive airways disorder22.03.01.0110.000112%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000224%Not Available
Hepatic lesion09.01.08.0050.000224%Not Available
Immunosuppression10.03.02.0010.000112%Not Available
Metastasis16.22.01.0010.000168%Not Available
Ureteral disorder20.06.01.0040.000112%Not Available
Renal impairment20.01.03.0100.002015%Not Available
Sinus disorder22.04.06.0020.000112%
Nail ridging23.02.05.0200.000112%
Heparin-induced thrombocytopenia24.01.01.020; 10.02.01.007; 01.08.01.0040.000246%Not Available
Poor quality sleep17.15.04.002; 19.02.05.0050.000168%Not Available
Middle ear effusion04.05.03.0010.000246%Not Available
Arterial occlusive disease24.04.02.0210.001007%Not Available
Increased upper airway secretion22.12.03.0070.000112%Not Available
Neutropenic colitis01.02.03.010; 07.08.01.0140.000168%Not Available
Anaphylactoid shock24.06.02.005; 10.01.07.0040.000224%Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene